CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology
Financing to support advancement of CREATE’s repeat dose capable CD19 targeted in vivo CAR-T therapy for autoimmune disease…